Product Information
GEMFIBROZIL 600 MG TABLET is a generic product labeled by Exelan Pharmaceuticals Inc., priced at $0.1038 per EA under NDC 76282022505. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 27, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
600 mg/1
Manufacturer
Exelan Pharmaceuticals Inc.NDC
76282022505
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GEMFIBROZILApproval Type
Generic (ANDA)
FDA Application
ANDA077836FDA Approved
7/27/2006
TE Code
AB
On Market Since
10/20/2006
Pharmacological Classes
Price Statistics
The NADAC for GEMFIBROZIL 600 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 3.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1038 per EA |
|---|---|
| All-time high | $0.1204 (Feb 12, 2014) |
| All-time low | $0.0831 (Dec 20, 2017) |
| 52-week high | $0.1045 |
| 52-week low | $0.1005 |
| Median price | $0.1038 |
| Average price | $0.1018 |
| Largest weekly change | -18.6% (Apr 17, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 14% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Exelan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Gemfibrozil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GEMFIBROZIL 600 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GEMFIBROZIL 600 MG TABLET, manufactured by Exelan Pharmaceuticals Inc., is $0.1038 per EA (NDC 76282022505), effective Sep 30, 2026.
How has the price of GEMFIBROZIL 600 MG TABLET changed over time?
Over the history we have for it, the NADAC for GEMFIBROZIL 600 MG TABLET has declined 3.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for GEMFIBROZIL 600 MG TABLET?
Since Nov 28, 2013, the NADAC for GEMFIBROZIL 600 MG TABLET has ranged from a low of $0.0831 (Dec 20, 2017) to a high of $0.1204 (Feb 12, 2014), with a median of $0.1038 per EA.
Are there cheaper alternatives to GEMFIBROZIL 600 MG TABLET?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GEMFIBROZIL 600 MG TABLET, is $0.0891 per EA — about 14% below GEMFIBROZIL 600 MG TABLET.
Who manufactures GEMFIBROZIL 600 MG TABLET?
GEMFIBROZIL 600 MG TABLET (NDC 76282022505) is labeled by Exelan Pharmaceuticals Inc., and CMS classifies it as a generic product.